Drug Trial Radar · NCT06172478
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
890
Planned (sponsor's estimate)
Start
Feb 26, 2024
Primary completion
Nov 19, 2030
Study completion Aug 19, 2031
Sponsor
- Lead sponsor
- Daiichi SankyoDaiichi Sankyo (DSNKY)
- Sponsor type
- Industry
- Collaborators
- Merck Sharp & Dohme LLC
- First posted
- Dec 15, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a proof-of-concept study designed to investigate HER3-DXd monotherapy in locally advanced unresectable or metastatic solid tumors. The study is enrolling cohorts of participants with melanoma \[cutaneous/acral\], squamous cell carcinomas of the head and neck (SCCHN), HER2-negative gastric cancer ovarian carcinoma, cervical cancer, endometrial cancer, bladder cancer, esophageal squamous cell carcinoma, pancreatic carcinoma, prostate cancer, second-line gastric cancer, lung cancer, breast, and cervical second-line/third-line (cervical 2L/3L) cancer.
Conditions
- Advanced Solid Tumor
- Melanoma
- Head and Neck Cancer
- Gastric Cancer
- Ovarian Carcinoma
- Cervical Cancer
- Endometrial Cancer
- Bladder Cancer
- Pancreatic Carcinoma
- Prostate Cancer
- Non-small Cell Lung Cancer (NSCLC)
- Lung Cancer
- Breast Cancer
- Esophageal Squamous Cell Carcinoma
Interventions
HER3-DXdDrug
Intravenous infusion 5.6 mg/kg administered Q3W on Day 1 of each 21-day cycle
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Objective Response Rate Assessed by Investigator Following HER3-DXd Monotherapy (All Cohorts Except Prostate Cancer Cohort)Time frame: Baseline up until documented progressive disease, death, lost to follow-up, or withdrawal by the participant, up to approximately 27 months
- Proportion of Participants Achieving a ≥50% Decrease in Prostate-specific Antigen (PSA) (Prostate Cancer Cohort Only)Time frame: Baseline, each cycle before infusion (each cycle is 21 days), and end of treatment, up to approximately 27 months
Locations
97 sites in 16 countries. Site status is shown where the registry gives one.
City of Hope
Duarte, California · Recruiting
Yale Cancer Center
New Haven, Connecticut · Recruiting
AdventHealth Medical Group Oncology Research at Celebration
Kissimmee, Florida · Recruiting
University of Illinois Cancer Center
Chicago, Illinois · Recruiting
Johns Hopkins University
Baltimore, Maryland · Recruiting
Maryland Oncology Hematology, PA
Rockville, Maryland · Recruiting
Health Partners Frauenshuh Cancer Center
Saint Louis Park, Minnesota · Recruiting
Health Partners Cancer Center at Regions Hospital
Saint Paul, Minnesota · Recruiting
Washington University, School of Medicine
St Louis, Missouri · Recruiting
Roswell Park Cancer Institute IDS
Buffalo, New York · Recruiting
Memorial Sloan Kettering Hospital
New York, New York · Recruiting
SCRI Oncology Partners
Nashville, Tennessee · Recruiting
The University of Texas MD Anderson Cancer Center
Houston, Texas · Recruiting
Fred Hutchinson Cancer Center
Seattle, Washington · Completed
Chris O'Brien Lifehouse
Camperdown, Australia · Recruiting
Icon Cancer Centre Chermside
Chermside, Australia · Recruiting
Monash Medical Centre Clayton
Clayton, Australia · Recruiting
Icon Cancer Centre Hobart
Hobart, Australia · Recruiting
Icon Cancer Centre Townsville
Hyde Park, Australia · Recruiting
Cliniques Universitaires Saint-Luc
Brussels, Belgium · Recruiting
UZA
Edegem, Belgium · Recruiting
Universitair Ziekenhuis Gent
Ghent, Belgium · Recruiting
Universitair Ziekenhuis Brussel
Jette, Belgium · Recruiting
UZ Leuven
Leuven, Belgium · Recruiting
Sunnybrook Research Institute
Toronto, Canada · Recruiting
Princess Margaret Cancer Centre
Toronto, Canada · Completed
BC Cancer - Vancouver
Vancouver, Canada · Recruiting
Cross Cancer Institute
Edmonton, Alberta, Canada · Recruiting
West China Hospital, Sichuan University
Chengdu, China · Recruiting
Sun Yat-sen University Cancer Center
Guangzhou, China · Recruiting
Chu Bordeaux
Bordeaux, France · Recruiting
Centre Georges Franăois Leclerc
Dijon, France · Recruiting
Hopital Claude Huriez - Chu Lille
Lille, France · Recruiting
Centre Léon Bérard
Lyon, France · Recruiting
Hăpital de La Timone
Marseille, France · Recruiting
Chu Nantes - Hătel Dieu
Nantes, France · Recruiting
Institut Claudius Regaud
Toulouse, France · Recruiting
ICL - Alexis Vautrin
Vandœuvre-lès-Nancy, France · Recruiting
Institut Gustave Roussy
Villejuif, France · Recruiting
Krankenhaus Nordwest GmbH
Frankfurt, Germany · Recruiting
Showing 40 of 97 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.